Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Ch...(ct for Resistant Mutants in H. in...),Health

Resistant Mutants in H. influenzae."

-- Poster C2-200, titled "Antimicrobial Resistance Patterns among

Streptococcus pneumoniae Isolated from Children in the U.S. 2005-2006

Faropenem Surveillance Study."

-- Poster D-238, titled "An Evaluation of Dried MIC Susceptibility Plate

Compared to the CLSI (M7) Reference Broth Microdilution Method with

the New Antimicrobial Agent, Faropenem."

-- Poster C2-214, titled "Comparative Affinity of Faropenem to Penicillin

Binding Proteins (PBPs) of Pneumococci with Varying Beta-Lactam

Susceptibilities."

Monday, September 17 at 1:00 PM, Hall D:

-- Poster L-480, titled "A Double-Blind, Randomized, Dose Ranging Study

to Evaluate the Safety of Faropenem Medoxomil (FM) at 300 or 600 mg

BID for Seven Days in Healthy Volunteers."

-- Poster L-481, titled "A Phase II Double-Blind, Randomized Trial

Comparing Faropenem Medoxomil at 300 mg BID for Seven Days and 600 mg

BID for Five Days in Subjects with Acute Maxillary Sinusitis Diagnosed

by Antral Tap."

Tuesday, September 18 at 11:15 AM, Hall D:

-- Poster G-980, titled "Monitoring Changes in Susceptibility of Middle

Ear Fluid (MEF), Nasopharyngeal (NP) and Oropharyngeal (OP) Pathogens

to Faropenem in a Phase II Acute Otitis Media (AOM) Study."

-- Poster G-983, titled "Use of Parent-reported Outcome Measure in Acute

Otitis Media Clinical Trials."

-- Poster G-987, titled "Dose-effect of Faropenem Medoxomil (FM) in the

Treatment of Acute Otitis Media."

Wednesday, September 19 at 11:15 AM, Hall D:

-- Poster A-1435, titled "Pharmacokinetic-Pharmacodynamic (PK-PD)

Assessment of Faropenem (FAR) in a Lethal Murine-Bacillus anthracis

(BA) Inhalation Post-Exposure Prophylaxis Model."

REP8839 Presentation

Thursday, Septem
'/>"/>